Drilldown: Medicines

Pharmacopedia is being built in public. Pages may be incomplete.About this site

Nav

Choose a table:

Medicines (732)

Medicines > duration

: 24 h

or 8-12 hours

or Hours per application

Use the filters below to narrow your results.

Bisoprolol (1) · Brimonidine (1) · Cefuroxime (axetil oral, sodium IV) (1) · Ciclopirox (1) · Ciprofloxacin (1) · Clotrimazole (1) · Hydroquinone (1) · Ketotifen (1) · Loperamide (1) · Memantine ER / Donepezil (1) · Metronidazole (1) · Mupirocin (1) · Nebivolol (1) · Nystatin (1)

Alphagan P (ophthalmic glaucoma), Mirvaso (topical rosacea) (1) · Bactroban, Centany (1) · Bystolic (1) · Ceftin (oral), Zinacef (IV) (1) · Cipro, Cipro XR, Ciloxan (ophthalmic) (1) · Flagyl, Metrocream, Metrogel, Metrogel-Vaginal, Noritate (1) · Imodium, Imodium A-D (1) · Lotrimin, Mycelex, Gyne-Lotrimin; OTC widely (1) · Lustra, EpiQuin Micro, Melquin, Tri-Luma (with tretinoin and fluocinolone) (1) · Mycostatin, Nystop, Nyamyc, Bio-Statin (1) · Namzaric (1) · Penlac (nail lacquer), Loprox (cream/lotion/shampoo) (1) · Zaditor, Alaway (ophthalmic, OTC); Zaditen (systemic, outside US) (1) · Zebeta (1)

None (7) · Donepezil: reversible AChE inhibitor, increases synaptic acetylcholine. Memantine: uncompetitive low-affinity NMDA receptor antagonist, dampens pathological glutamate overactivation while preserving normal synaptic signaling. Targets two distinct mechanisms in Alzheimer's. (1) · Highly β1-selective adrenergic antagonist. Greater selectivity than metoprolol or atenolol. (1) · The d-enantiomer is a highly β1-selective antagonist; the l-enantiomer triggers endothelial nitric-oxide–mediated vasodilation. Unique among beta blockers for this NO mechanism. (1) · '"`UNIQ--vote-000009FD-QINU`"' Active against gram-positive cocci including MRSA; the unique target underlies the absence of cross-resistance with other antibiotic classes. High-level resistance (plasmid-mediated mupA) is rising and limits prolonged or repeated use'"`UNIQ--ref-000009FE-QINU`"'. (1) · '"`UNIQ--vote-00000D11-QINU`"' Same mechanistic family as amphotericin B but with prohibitive systemic toxicity at therapeutic doses, hence restriction to topical and luminal-gut indications. No clinically meaningful resistance after decades of use'"`UNIQ--ref-00000D12-QINU`"'. (1) · '"`UNIQ--vote-00001233-QINU`"' Onychomycosis cure rates with nail lacquer are modest (mycologic cure ~30-50%, complete cure ~5-12% at 48 weeks); oral terbinafine remains substantially more effective when systemic therapy is acceptable'"`UNIQ--ref-00001234-QINU`"'. (1) · '"`UNIQ--vote-00001284-QINU`"' Systemic oral ketotifen (available outside US) has historical use for asthma adjunct therapy via the same dual mechanism, but oral use produces sedation and weight gain — the topical ophthalmic application largely avoids both'"`UNIQ--ref-00001285-QINU`"'. (1)

2.5–5 mg daily (HTN); 1.25 mg daily (HFrEF, slow titration) (1) · 250-500 mg PO BID × 7-14 days; IV 1.5 g q8h for serious infections (1) · 4 mg PO initially, then 2 mg after each loose stool, '''not to exceed 16 mg/d''' (8 mg OTC); chronic-use lower (1) · 5 mg daily (1) · 500 mg PO TID × 7-10 days (most indications); 2 g single dose for trichomoniasis; 500 mg IV q8h for severe anaerobic infection; rectal 1 g BID (1) · 500-750 mg PO BID; 400 mg IV q8-12h (1) · Apply thin layer to hyperpigmented areas BID; limit to 4-6 month courses to avoid ochronosis (1) · For patients already stable on memantine 28 mg/d + donepezil 10 mg/d, switch to one capsule daily of equivalent strength (1) · Ophthalmic 1 drop in affected eye(s) TID; topical Mirvaso 0.33% gel applied to face daily (1) · Ophthalmic 1 drop in each eye every 8-12 hours (1) · Oral: 4-6 mL (400,000-600,000 units) suspension QID swish-and-swallow; topical: BID-QID; vaginal tablet 1 daily for 2 weeks (1) · Topical cream/lotion BID; shampoo twice weekly; nail lacquer (Penlac) once daily for up to 48 weeks (1) · Topical: 1% cream BID × 2-4 weeks; vaginal: 1% or 2% cream nightly × 7 days, or 100/200/500 mg vaginal tablet single or 3-day regimens; troche: 10 mg PO five times daily × 2 weeks for thrush (1) · Topical: apply small amount to affected area TID × 5-10 days; nasal: apply half the contents of a single-use tube into each nostril BID × 5 days (1)

0.025%, 0.035% ophthalmic solutions (1) · 0.1%, 0.15%, 0.2% ophthalmic solutions; 0.33% topical gel; combinations with timolol (Combigan) and brinzolamide (Simbrinza) (1) · 0.77% topical cream, lotion, suspension; 1% shampoo; 8% nail lacquer (Penlac) (1) · 1% topical cream, lotion, solution; 1%, 2% vaginal cream; 100, 200, 500 mg vaginal tablets; 10 mg oral troches; combination with betamethasone (Lotrisone, Rx) (1) · 100,000 units/mL oral suspension; 500,000 unit tablets; 100,000 units/g cream, ointment, powder; vaginal tablets (1) · 125, 250, 500 mg tablets; 125 mg/5 mL, 250 mg/5 mL suspension; 750 mg, 1.5 g IV vials (1) · 2 mg capsules and tablets; 1 mg/5 mL oral solution; combined with simethicone (Imodium Multi-Symptom) (1) · 2% ointment; 2% cream; 2% nasal ointment (Bactroban Nasal) (1) · 2.5, 5, 10, 20 mg tabs (1) · 250, 500 mg tablets; 750 mg ER; 500 mg/100 mL IV; 0.75-1% topical gel/cream; 0.75% vaginal gel; suppository (1) · 250, 500, 750 mg IR tablets; 500, 1000 mg ER tablets (XR); 250, 500 mg/5 mL oral suspension; 200, 400 mg IV; 0.3% ophthalmic solution and ointment; 0.2% otic (1) · 4% prescription cream/lotion; OTC 2% withdrawn in US (2020 CARES Act); compounded higher strengths available (1) · 5, 10 mg tabs (1) · 7/10, 14/10, 21/10, 28/10 mg ER capsules (memantine ER / donepezil) (1)

1 drop per eye q8-12h (1) · 1 g/d (oral); 6 g/d (IV) (1) · 16 mg/d (8 mg/d OTC) (1) · 20 mg/d (1) · 28/10 mg/d (1) · 4% topical; limit duration of use (1) · 40 mg/d (1) · BID topical; once daily nail lacquer (1) · Indication-specific (1) · Limit topical to 10-day courses to reduce resistance pressure (1) · TID per eye (1) · Topical: BID; troche: 5×/day (1) · ~1500 mg/d (oral); 1200 mg/d (IV) (1) · ~4 g/d (severe systemic infection) (1)

IM (1) · intranasal (1) · IV (3) · Oral (6) · Oral (capsule whole or opened/sprinkled on applesauce) (1) · Oral (topical action; minimal systemic absorption) (1) · oral troche (1) · otic (1) · Topical (6) · Topical ophthalmic (3) · topical skin (1) · vaginal (3)

1–2 h (2) · 30-60 minutes (1) · Component effects accumulate over weeks (1) · Days (2) · Days for dermatophyte clearance; nail clearance over months (1) · Hours (3) · IOP lowering at 1 hour; max at 2-3 hours (1) · Symptom relief within days (1) · Visible lightening at 4-12 weeks (1) · Within minutes (1)

4 hours'"`UNIQ--ref-00000938-QINU`"' (1) · 6-8 hours'"`UNIQ--ref-00000BEB-QINU`"' (1) · 9–12 h (1) · Not meaningfully described (minimal systemic absorption from topical use)'"`UNIQ--ref-00000F45-QINU`"' (1) · Not meaningfully described (not systemically absorbed)'"`UNIQ--ref-00000D17-QINU`"' (1) · Not meaningfully described (topical local action)'"`UNIQ--ref-00001239-QINU`"' (1) · Not meaningfully described for ophthalmic use'"`UNIQ--ref-00001287-QINU`"' (1) · Not meaningfully described for topical use'"`UNIQ--ref-00000A02-QINU`"' (1) · Not meaningfully described — topical local action with minimal systemic absorption'"`UNIQ--ref-00001218-QINU`"' (1) · ~1.5 hours'"`UNIQ--ref-00000FF9-QINU`"' (1) · ~10 h (CYP2D6 extensive metabolizers); up to 31 h (poor metabolizers) (1) · ~3 hours'"`UNIQ--ref-000010D1-QINU`"' (1) · ~60–80 h (memantine); ~70 h (donepezil) (1) · ~9-14 hours'"`UNIQ--ref-00000FD2-QINU`"' (1)

Essentially zero systemic absorption from oral or topical routes — the topical-action-only profile is the basis of its safety'"`UNIQ--ref-00000D18-QINU`"' (1) · Topical with limited but measurable systemic absorption'"`UNIQ--ref-00001219-QINU`"' (1) · Topical with minimal systemic absorption'"`UNIQ--ref-0000123A-QINU`"' (1) · Topical with minimal systemic absorption'"`UNIQ--ref-00001288-QINU`"' (1) · Topical: minimal systemic; troche: ~3% systemic'"`UNIQ--ref-00000F46-QINU`"' (1) · Topical; clinically meaningful systemic absorption can produce systemic α2 effects (somnolence, hypotension), especially in children'"`UNIQ--ref-000010D2-QINU`"' (1) · Topical; minimal systemic absorption'"`UNIQ--ref-00000A03-QINU`"' (1) · ~0.3% (oral; extensive first-pass via CYP3A4 and P-glycoprotein-mediated efflux at the intestinal and blood-brain barriers limit systemic and CNS exposure at therapeutic doses)'"`UNIQ--ref-00000FD3-QINU`"' (1) · ~100% both components (1) · ~12% (extensive metabolizers); ~96% (poor metabolizers) (1) · ~37% (oral, as axetil prodrug; food modestly improves absorption)'"`UNIQ--ref-00000FFA-QINU`"' (1) · ~70% (oral; reduced by divalent cations — antacids, iron, calcium, dairy)'"`UNIQ--ref-00000939-QINU`"' (1) · ~80% (oral)'"`UNIQ--ref-00000BEC-QINU`"' (1) · ~90% (low first-pass) (1)

'''Avoid in pregnancy where alternatives exist''' (animal cartilage toxicity; class-wide concern); use only when benefit clearly outweighs.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Category C (2) · Generally avoided in pregnancy.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Generally considered acceptable when needed.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Generally considered safe (minimal systemic absorption).[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Generally considered safe (minimal systemic exposure).[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Generally considered safe after the first trimester; first-trimester use weighed against indication.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Generally considered safe in pregnancy (no systemic absorption).[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Generally considered safe in pregnancy.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Generally considered safe; minimal systemic exposure.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Limited data.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Not relevant (geriatric problem) (1) · Topical and vaginal generally considered safe; widely used.[[[Pharmacopedia:Citation needed|citation needed]]] (1)

None (1) · OTC (lower strengths) and [[USLegal:Prescription only|Rx-only]] (combination with betamethasone) in US (1) · OTC in US (2) · Rx-only in US (3) · [[USLegal:Prescription only|Rx-only]] in US (6) · [[USLegal:Prescription only|Rx-only]] in US since 2020 (OTC 2% formulations withdrawn under CARES Act due to safety concerns) (1)

Showing below up to 14 results in range #1 to #14.

B